EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?

Anurag S Rathore iD, Garima Thakur, Nikhil Kateja

Biotechnology and Bioengineering · 2023-02 · 120 (2) · 333-351

DOI: 10.1002/bit.28235 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 28.09.2022. Verfasst von Anurag S Rathore und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India. Hauptthemen laut MEDLINE: Technology, Pharmaceutical, Biological Products. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 139 Literaturangaben. Gefördert von: Council of Scientific and Industrial Research, India, Tata Consultancy Services, Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Continuous integrated bioprocessing has elicited considerable interest from the biopharma industry for the many purported benefits it promises. Today many major biopharma manufacturers around the world are engaged in the development of continuous process platforms for their products. In spite of great potential, the path toward continuous integrated bioprocessing remains unclear for the biologics industry due to legacy infrastructure, process integration challenges, vague regulatory guidelines, and a diverging focus toward novel therapies. In this article, we present a review and perspective on this topic. We explore the status of the implementation of continuous integrated bioprocessing among biopharmaceutical manufacturers. We also present some of the key hurdles that manufacturers are likely to face during this implementation. Finally, we hypothesize that the real impact of continuous manufacturing is likely to come when the cost of manufacturing is a substantial portion of the cost of product development, such as in the case of biosimilar manufacturing and emerging economies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology, PharmaceuticalBiological ProductsDrug Industry

Stichwörter der Autor:innen

biopharmaceuticalscontinuous integrated bioprocessingmanufacturing platformsprocess integration

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Chemical Engineering, Indian Institute of Technology, New Delhi, India.

ORCID-Profile: Anurag S Rathore

Förderung

  • Council of Scientific and Industrial Research, India
  • Tata Consultancy Services
  • Department of Biotechnology, Ministry of Science and Technology, India

Zitieren

APA

Rathore, A. S., Thakur, G., & Kateja, N. (2023). Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?. Biotechnology and Bioengineering, 120(2), 333-351. https://doi.org/10.1002/bit.28235

Vancouver

Rathore AS, Thakur G, Kateja N. Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?. Biotechnology and Bioengineering. 2023;120(2):333-351. doi:10.1002/bit.28235

BibTeX
@article{Rathore2023,
  author = {Rathore, Anurag S and Thakur, Garima and Kateja, Nikhil},
  title = {Continuous integrated manufacturing for biopharmaceuticals: A new paradigm or an empty promise?},
  journal = {Biotechnology and Bioengineering},
  year = {2023},
  volume = {120},
  number = {2},
  pages = {333--351},
  doi = {10.1002/bit.28235}
}
Kostenlos starten →